Skip Navigation

Innovations

  • Our Mission

    To actively accelerate innovations to benefit patients, society, and the Dana-Farber Cancer Institute. We team with investigators to identify new discoveries and generate alliances to move science from bench to clinic for maximum impact.

    Our Vision

    To spark and fuel a spirit of innovation across the organization by providing effective tools to continuously question, create, and imagine what else might be possible.

    Collaboration Opportunities

    In collaborating with Dana-Farber, your organization will have access to the Institute's specialized expertise, and to the unique array of core facilities needed to explore new areas of research. Learn more about Dana-Farber Centers that are interested in partnering with industry. Explore Dana-Farber's extensive Core Facilities. And discover more opportunities to collaborate.

  • BODFI statistics for 2019
  • In partnership with the Innovation Office, Dana-Farber makes publicly available a list of FDA-approved therapeutics and diagnostics in which the Institute has a financial interest.
    View the list

  • Technology News

    constantine-mitsiades

    Pleiotropic Mechanisms Drive Endocrine Resistance in the 3D Bone Microenvironment

    Hormonal therapy (HT) inhibits the growth of hormone receptor-positive (HR+) breast (BrCa) and prostate (PrCa) cancers, but resistance to HT frequently develops within the complex metastatic microenvironment of the host organ (often the bone), a setting poorly recapitulated in 2D culture systems. To address this limitation and to study the potential contribution of cell non-autonomous mechanisms to endocrine resistance, first author Eugen Dhimolea, PhD, and senior author Constantine Mitsiades, MD, PhD, share a new study in American Association for Cancer Research, wherein they examined the responses of BrC and PrCa cells to HT in 3D culture conditions in the presence vs. absence of bone marrow stromal cells (BMSC) in the microenvironment of key metastatic sites.

    Jerome_Ritz_SOG_9413_09

    Dana-Farber Collaborates with Mass Eye and Ear to Rebuild Damaged Corneas Using Patient-Derived Stem Cells

    Under the direction of principal investigator Ula V. Jurkunas, MD, a cornea and refractive surgeon at the Massachusetts Eye and Ear Infirmary, and Jerome Ritz, MD, Senior Director of the Connell and O'Reilly Families Cell Manipulation Core Facility (CMCF) at Dana-Farber, surgeons and researchers collaborated in four cases of corneal stem cell transplant, which represent the first procedures of their kind to occur in the United States and are all part of an ongoing clinical trial supported by the National Eye Institute of the National Institutes of Health (NIH).

    Deborah Schrag, MD, MPH

    Dana-Farber Opens Clinical Trial to Evaluate Next-Generation Sequencing Blood Test to Detect Cancer

    Dana-Farber is opening a new clinical trial for enrollment to evaluate a minimally-invasive blood test that will look for the earliest signs of cancer which may be present in the blood stream before the disease has progressed to a point where it causes symptoms. The clinical trial uses a blood test developed by GRAIL, Inc. that could detect more than 50 types of cancer, as well as their location within the body. In previous studies, cancers were detected across all stages (stage I–III sensitivity: 43.9%; stage I–IV sensitivity: 54.9%) at a specificity of >99% and a single false positive rate of <1%. The blood test uses next-generation sequencing to analyze the methylation pattern on the DNA of cancer cells that are circulating in the bloodstream.

    Peter_Sicinski_SOG_7139_11

    Increased Lysosomal Biomass is Responsible for the Resistance of Triple-Negative Breast Cancers (TNBC) to Treatment with CDK4/6 Inhibitors

    Consistent with their growth-promoting roles, overexpression of cyclin D–CDK4/6 kinases has been documented in a large number of human malignancies, including breast cancer. However, in contrast to hormone receptor–positive breast cancers, which initially respond to treatment with CDK4/6 inhibitors like palbociclib, triple-negative breast cancers (TNBC) show an intrinsic resistance to CDK4/6 inhibition.

    Coming Soon: Our Quarterly Newsletter

    Stay current with Dana-Farber technology news, transactions, patents, publications, events, and more.